CA2249641A1 - Inhibiteurs de farnesyl-proteine transferase - Google Patents

Inhibiteurs de farnesyl-proteine transferase Download PDF

Info

Publication number
CA2249641A1
CA2249641A1 CA002249641A CA2249641A CA2249641A1 CA 2249641 A1 CA2249641 A1 CA 2249641A1 CA 002249641 A CA002249641 A CA 002249641A CA 2249641 A CA2249641 A CA 2249641A CA 2249641 A1 CA2249641 A1 CA 2249641A1
Authority
CA
Canada
Prior art keywords
substituted
alkyl
aryl
unsubstituted
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002249641A
Other languages
English (en)
Inventor
Samuel L. Graham
John S. Wai
Theresa M. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609667.2A external-priority patent/GB9609667D0/en
Application filed by Individual filed Critical Individual
Publication of CA2249641A1 publication Critical patent/CA2249641A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés qui inhibent la farnésyl-protéine transférase (FTase) et la farnésylation de la protéine Ras oncogène. L'invention a en outre pour objet des compositions chimiothérapeutiques contenant les composés de cette invention et des procédés pour inhiber la farnésyl-protéine transférase et la farnésylation de la protéine Ras oncogène.
CA002249641A 1996-04-03 1997-03-27 Inhibiteurs de farnesyl-proteine transferase Abandoned CA2249641A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1479396P 1996-04-03 1996-04-03
US60/014,793 1996-04-03
GBGB9609667.2A GB9609667D0 (en) 1996-05-09 1996-05-09 Inhibitors of farnesyl-protein transferase
GB9609667.2 1996-05-09

Publications (1)

Publication Number Publication Date
CA2249641A1 true CA2249641A1 (fr) 1997-10-09

Family

ID=26309290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249641A Abandoned CA2249641A1 (fr) 1996-04-03 1997-03-27 Inhibiteurs de farnesyl-proteine transferase

Country Status (5)

Country Link
EP (1) EP0897303A1 (fr)
JP (1) JP2000508631A (fr)
AU (1) AU717190B2 (fr)
CA (1) CA2249641A1 (fr)
WO (1) WO1997036605A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015817A (en) * 1996-12-05 2000-01-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2276081A1 (fr) * 1996-12-30 1998-07-09 Lekhanh O. Tran Inhibiteurs de farnesyl-proteine transferase
CA2312366A1 (fr) * 1997-12-04 1999-06-10 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
TR200002182T2 (tr) * 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
FR2819509B1 (fr) * 2001-01-18 2004-04-16 Servier Lab Nouveaux composes cycloheptene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2819511A1 (fr) * 2001-01-18 2002-07-19 Servier Lab Nouveaux composes azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2819510B1 (fr) * 2001-01-18 2003-10-31 Servier Lab Nouveaux composes cyclo[c] azepane, leur procede de preparation et les compositions pharmaceutiques qui le contiennent
FR2819512B1 (fr) * 2001-01-18 2003-02-21 Servier Lab Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003018554A1 (fr) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 3-substitue-3-(substitue sulfonyl ou sulfanyl)pyrrolidine-2,5-diones utiles pour l'inhibition de la farnesyl-proteine transferase
WO2003024401A2 (fr) 2001-09-18 2003-03-27 Bristol-Myers Squibb Company Piperazinones de modulation de l'activite des recepteurs des chimiokines
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
CA2678577A1 (fr) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Inhibiteurs d'uree et de carbamate de 11b-hydroxysteroide deshydrogenase 1 cycliques
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2010010157A2 (fr) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibiteurs de la 11 bêta-hydroxystéroïde déshydrogénase 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5679997B2 (ja) 2009-02-04 2015-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
EP2448928B1 (fr) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1
WO2011159760A1 (fr) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
WO2011161128A1 (fr) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones comme inhibiteurs de 11-β-hsd1 pour le traitement de troubles métaboliques
WO2012059416A1 (fr) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Combinaisons pharmaceutiques destinées au traitement de troubles du métabolisme

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2172125A1 (fr) * 1993-09-30 1995-04-06 S. Jane Desolms Inhibiteurs de farnesyl-proteine transferase
AU1615895A (en) * 1994-03-31 1995-10-12 Bristol-Myers Squibb Company Imidazole-containing inhibitors of farnesyl protein transferase
US5576313A (en) * 1994-08-29 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
JP2000508631A (ja) 2000-07-11
WO1997036605A1 (fr) 1997-10-09
EP0897303A4 (fr) 1999-02-24
EP0897303A1 (fr) 1999-02-24
AU717190B2 (en) 2000-03-23
AU2542597A (en) 1997-10-22

Similar Documents

Publication Publication Date Title
US5919785A (en) Inhibitors of farnesyl-protein transferase
US5854265A (en) Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) Arylheteroaryl inhibitors of farnesyl-protein transferase
US5854264A (en) Inhibitors of farnesyl-protein transferase
US5965578A (en) Inhibitors of farnesyl-protein transferase
AU716338B2 (en) Inhibitors of farnesyl-protein transferase
US5883105A (en) Inhibitors of farnesyl-protein transferase
AU715603B2 (en) Inhibitors of farnesyl-protein transferase
CA2249641A1 (fr) Inhibiteurs de farnesyl-proteine transferase
US5874452A (en) Biheteroaryl inhibitors of farnesyl-protein transferase
US5885995A (en) Inhibitors of farnesyl-protein transferase
US5939557A (en) Inhibitors of farnesyl-protein transferase
WO1997036897A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
WO1997036901A1 (fr) Inhibiteurs de transferase de farnesyl-proteine
AU715667B2 (en) Inhibitors of farnesyl-protein transferase
US5780492A (en) Inhibitors of farnesyl-protein transferase
WO1997036898A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
US5624936A (en) Inhibitors of farnesyl-protein transferase
EP0891343A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
AU706314B2 (en) Inhibitors of farnesyl-protein transferase
CA2250460A1 (fr) Inhibiteurs de transferase de farnesyl-proteine
US6001835A (en) Inhibitors of farnesyl-protein transferase
EP0891353A1 (fr) Inhibiteurs de farnesyle-proteine transferase
AU715604B2 (en) Inhibitors of farnesyl-protein transferase
CA2250587A1 (fr) Inhibiteurs de farnesyl-proteine transferase

Legal Events

Date Code Title Description
FZDE Dead